UCBJF:OTCMKTS
UCB SA
240,24 $
arrow_upward
+1,82%(+4,30) 1D
15 қаз., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJF...
Open
240,24 $
High
240,24 $
Low
240,24 $
Mkt. cap
39,41 млрд
Avg. vol.
139,00
Volume
10,00
52-wk high
345,39 $
52-wk low
219,60 $
Beta
0,58
Shares outstanding
194,51 млн
No. of employees
9 мың
Open
240,24 $
High
240,24 $
Low
240,24 $
Mkt. cap
39,41 млрд
Avg. vol.
139,00
Volume
10,00
52-wk high
345,39 $
52-wk low
219,60 $
Beta
0,58
Shares outstanding
194,51 млн
No. of employees
9 мың
News stories
From web sources and news partners
ad-hoc-news.de
·
1 сағат бұрын
UCB revises Bimzelx potential above EUR 7 billion: UCB stock sits 30.28 percent below its high
ad-hoc-news.de
·
1 күн бұрын
UCB dedicates Georgia campus as UCB stock sits 29.15 percent below its high
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB SA
CEOJean-Christophe Tellier
Employees9 мың
Founded1928 ж. 18 қаң.
Headquarters-
SectorPharmaceutical industry
Websiteucb.com